Hexarelin
$Potent GH secretagogue; Higher endocrine spillover and desensitization risk
Hexarelin, also called examorelin, is a synthetic GH secretagogue in the GHRP family. It is known for strong GH release and potential cardiovascular research interest.
The mechanism is stronger than the wellness evidence. It can trigger hormone changes, but long-term body-composition, recovery, or longevity claims remain separate questions. Know that stronger is not automatically better. Monitor IGF-1, glucose, edema, blood pressure, prolactin/cortisol context, and loss of effect over time.
Classification details
- Hexarelin is a synthetic hexapeptide and potent agonist of the growth hormone secretagogue receptor.
- It is chemically related to older GHRPs and is generally considered more intense and more prone to desensitization than gentler options.
- Hexarelin is a potent synthetic GHS-R agonist in the GH-secretagogue family. It is distinct from ipamorelin because it is less selective and has stronger desensitization and off-target endocrine concerns.
- Direct pituitary stimulation: binds GHS-R receptors to release a large GH pulse, widely considered the most potent GHRP for the sheer height of the spike.
- Somatostatin inhibition: suppresses the body's natural brake on GH release.
- Cardioprotection: uniquely also binds CD36 receptors in the heart and blood vessels, and research shows it can protect heart cells from ischemic damage.
- Tissue repair: like other GHRPs it raises IGF-1, aiding muscle protein synthesis and systemic repair.
- Hormonal bleed: more than ipamorelin, it can nudge ACTH, cortisol, and prolactin in some settings.
- It stimulates GH release via GHS-R and may affect ACTH/cortisol/prolactin more than selective secretagogues. Cardiac research signals exist, but that does not make it a cardioprotective therapy.
- Heart-failure recovery: data suggests it helps restore cardiac function after myocardial infarction by reducing scar tissue and improving ejection fraction.
- Bone density: particularly effective at increasing bone mineral density, making it a candidate for osteoporosis research.
- Neuroprotection: recent findings explore reduced brain inflammation after traumatic brain injury.
- Fast desensitization: it is more prone to tachyphylaxis (rapidly diminishing response) than ipamorelin or GHRP-2, a practical limit on frequent use.
- Caveat: the cardiovascular literature is mechanistic and small-scale, and does not generalize into an anti-aging or performance therapy.
- Human endocrine data support GH stimulation. Long-term wellness outcomes are not established. Attenuation with repeated exposure is better supported for hexarelin-like agents than for many peptide protocols.
The entries below separate approved-label, clinical, preclinical, and community-reported contexts. They are reference material, not personalized dosing instructions.
- Protocol 1: Maximum GH Pulse [Research/Experimental]; Route: Subcutaneous (SC); Dose: 100 mcg; Frequency: 2 to 3 times daily; Timing: Fasted (Morning/Night); Duration: 4 to 8 weeks (Max); Status: Not FDA-approved as written.
- Protocol 2: Cardiovascular Support (Research) [Research/Experimental]; Route: Subcutaneous (SC); Dose: 50 mcg – 100 mcg; Frequency: Once daily (Nightly); Timing: Nightly; Duration: 2 to 4 weeks; Status: Not FDA-approved as written.
- Cycling/breaks are more defensible here than with ipamorelin because of desensitization concerns. Still, exact 5-on/2-off scheduling is a convention, not a proven optimum.
- Time until steady state: roughly 5 to 6.5 hours by half-life math.
- Half-life basis: a human kinetics/disposition study reported an IV half-life of 75.9 +/- 9.3 minutes and subcutaneous bioavailability around 64%, with no clear accumulation across studied subcutaneous doses.
- A 6-hour exposure estimate does not mean the desired outcome appears in 6 hours. It means drug exposure would approach a plateau with repeat dosing at a constant interval, while the GH pulse itself rises and falls over a shorter window.
- Because hexarelin is used for pulse signaling and can desensitize receptors, monitoring response and side effects matters more than chasing constant exposure.
- Comparison note: Hexarelin generally produces a stronger GH pulse and higher desensitization risk than GHRP-2 or ipamorelin. Ipamorelin is usually framed as cleaner, while hexarelin is framed as more forceful.
- Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
- Short exposure and strong receptor signaling can coexist. Receptor responsiveness, pituitary reserve, and downstream IGF-1 matter more than half-life alone.
- Mechanistic pairings include a GHRH analog such as CJC-1295 without DAC or sermorelin.
- BPC-157 pairings are anecdotal injury-recovery stacks, not controlled evidence.
- Avoid combining with other GH secretagogues or GH without clinician oversight because side effects can compound.
- Stacking with GHRH analogs can amplify GH/IGF-1. Stacking with other appetite/metabolic agents can complicate glucose and fluid effects. Avoid stacking with CJC-DAC unless monitoring is explicit.
- Risks include flushing, headache, lethargy, edema, numbness/tingling, glucose disruption, cortisol/prolactin changes, blood-pressure effects, and rapid loss of response with frequent exposure.
- Avoid in active malignancy, uncontrolled diabetes, untreated sleep apnea, pregnancy, or significant cardiovascular instability unless in a formal protocol.
- Main concerns include cortisol/prolactin spillover, edema, numbness, glucose changes, appetite, desensitization, and theoretical cardiac/endocrine complexity. It is not the gentle default GH secretagogue.
- Monitor IGF-1, fasting glucose, HbA1c, blood pressure, edema, sleep apnea symptoms, prolactin/cortisol context, and symptom response.
- Cardiovascular research settings may use echocardiography or functional endpoints.
- Track IGF-1, fasting glucose/A1c, edema, sleep apnea symptoms, blood pressure, prolactin/cortisol if symptomatic, and changes in libido or mood.
- Hexarelin is not FDA-approved for general human use and is prohibited for athletes under peptide-hormone/secretagogue anti-doping rules.
- It is generally encountered as a research chemical rather than a regulated clinical product.
- Hexarelin is not FDA-approved for anti-aging/body composition. Anti-doping and research-market caveats matter here.